Tony's Diary Package — page 1027

ctoberSeptember 30: NIH expanded research to improve COVID-19 testing among underserved and vulnerable populations as part of the RADx initiative, the RADx Underserved Populations (RADxUP) program. Press release Blurb: NIH expanded RADx initiative to improve COVID-19 testing in underserved populations. Image: 9.30.20 RADx UP October 2: Quidel Sofia 2, the first point-of-care test to detect COVID-19 supported by NIH's RADx initiative, receives emergency use authorization (EUA) from the FDA. Blurb: First RADX-supported COVID test received EUA. Image: 2.2.20 Test Kit December 11: The ACTT-2 trial found that baricitinib, an anti-inflammatory drug, reduced time to recovery for people hospitalized with COVID-19 who were treated with remdesivir. Press release Blurb: Trial results showed remdesivir in combination with anti-inflammatory drug baricitinib reduced hospital recovery time Image: https://www.shutterstock.com/image-photo/medication-prepared-people-affected-bycovid19-1970653763 December 15: The first over-the-counter COVID-19 test, developed with support from NIH's RADx initiative, received an FDA emergency use authorization. Blurb: First RADx-supported over-the-counter COVID-19 test received EUA. Image: 12.15.20 RADx OTC December 18: FDA authorized the NIH-Moderna vaccine for emergency use for people 18 years of age and older. The NIH-Moderna vaccine went on to receive authorization for various age groups and is now available for everyone over the age of 6 months. Blurb: FDA grants EUA to NIH/Modera vaccine Image: https://www.shutterstock.com/image-illustration/cracow-malopolskie-poland-october10-2021-1891094320 January 5: NIH's RADx launched an interagency variant task force to evaluate the impact of new variants on the performance of all authorized point of care and over the counter diagnostics, as well as tests